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JOURNAL OF HEPATOLOGYTo the Editor:
We thank Professors Reiberger and Peck-Radosavljevic for
their comment to our article [1], and generally agree with them
that results coming from any post hoc analysis need to be
interpreted with caution. With respect to our sub-analysis of
the MIST study [2], the main concerns mostly rely on the lack
of stratiﬁcation for ﬁbrosis stage in the randomization process,
as well as the lack of data on the Interleukin 28B (IL28B)
genotype. Indeed, at the time of preparation of the manuscript
we had not run the IL28B test in the entire study cohort, but
are now able to provide the complete results for the cohort of
HCV-1 and 4 patients, a patient population where the IL28B
genotype has been shown to be a strong predictor of treatment
outcome [3–5]. The prevalence of the non-responsive T allele of
the rs12979860 single nucleotide polymorphism did not differ
between the two treatment regimens (a2a: 76% vs. a2b: 72%).
The same was true even when patients were divided into those
with a staging <3 (a2a: 81% vs. a2b: 66%), and those with a
staging P3 (a2a: 72% vs. a2b: 76%) (Table 1). When SVR rates
were analyzed by combining the staging score and the IL28B
genotype, they were consistently higher in patients receiving
PegIFNa2a, reaching statistical signiﬁcance in the T allele
patients with advanced ﬁbrosis (a2a: 34% vs. a2b: 8%; p =
0.003) (Table 1). This information further supports that, at least
in our study, the PegIFNa2a regimen was generally more effec-
tive than the PegIFNa2b regimen in the most difﬁcult-to-cure
patients, such as those with advanced ﬁbrosis and unfavorable
IL28B genotype, while the two regimens were somewhat similar
in terms of SVR rates in patients with baseline factors predictive
of treatment success. We can reasonably exclude PegIFN/RBV
dose reductions or treatment discontinuations to have played a
role in our results, as they did not differ between the regimens
even when analyzed on the basis of degree of ﬁbrosis, as already
discussed in detail in our paper. Indeed, the higher prevalence of
treatment discontinuations in the PegIFNa2b arm was actually
the consequence of more patients failing to respond on-treat-
ment, and thus meeting the week 12 or 24 stopping rules, com-
pared to the PegIFNa2a arm (a2a: 13% vs. a2b: 23%). In fact the
discontinuation rates for non-virological reasons were similar
between the two regimens (a2a: 8% vs. a2b: 10%).
In conclusion, although we do not have a clear-cut answer as
to why the PegIFNa2b regimen was associated with hypo-Table 1. Sustained virological response rates in HCV-1 and 4 patients.
PegIFNα2a + RBV
(n = 108°)
PegIFNα2b + RBV
(n = 113)
p*
Staging 0-2
IL28B CC 7/8 (88%) 11/17 (64%) 0.3
IL28B CT/TT 13/35 (37%) 11/33 (33%) 1
Staging 3-6
IL28B CC 16/18 (89%) 10/15 (67%) 0.2
IL28B CT/TT 16/47 (34%) 4/48 (8%) 0.003
One patient could not be tested for IL28B rs12979860 genotype.
⁄Fisher exact probability test.
Journal of Hepatology 20responsiveness in patients with advanced ﬁbrosis, and can only
speculate that it might be for the different pharmacokinetic
parameters of the two PegIFNs [6], we can certainly exclude
skewed distribution of the IL28B genotype as well as reduced
patients’ compliance to be the culprits.
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